Strides Pharma Science Q2 Results FY27: Revenue Rises 17.11% to Rs 1,429.73 Cr, PAT Up 1.98% to Rs 134.12 Cr
- October 29, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Strides Pharma Science Q2 Results FY27 were declared on 29 October 2026 for the July to September 2026 quarter. In these quarterly results, consolidated revenue came in at Rs 1,429.73 Cr, up 17.11% from Rs 1,220.83 Cr a year earlier. Net profit rose 1.98% to Rs 134.12 Cr from Rs 131.52 Cr, while Operating Profit reached Rs 250.91 Cr, a YoY growth of 8.35%.
Strides Pharma Science Ltd (STAR) Q2 Results FY27 announced on 29 October 2026, covering the company’s financial performance for the July to September quarter. The results date brought consolidated revenue of Rs 1,429.73 Cr and PAT of Rs 134.12 Cr into view. Strides Pharma Science Q2 Results FY27 therefore pair 17.11% revenue growth with a 1.98% rise in profit after tax, measured against the same quarter last year.
This Strides Pharma Science Q2 Results article covers the financial highlights, the business drivers, the outlook and the risks in one connected sequence. The results analysis starts with the Financial Highlights table below, which sets each reported line beside the figure from the same quarter of last year.
Click Here – Get Free Investment Predictions
Strides Pharma Science Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 1429.73 Cr | Rs 1220.83 Cr | +17.11% YoY |
| Operating Profit | Rs 250.91 Cr | Rs 231.57 Cr | +8.35% YoY |
| Net Profit (PAT) | Rs 134.12 Cr | Rs 131.52 Cr | +1.98% YoY |
Source: company filing for Strides Pharma Science Q2 Results FY27, 29 October 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Strides Pharma Science Q2 Results: What Stands Out
- Revenue of Rs 1,429.73 Cr was up 17.11% from Rs 1,220.83 Cr, a double-digit YoY growth rate across the quarter.
- Net profit of Rs 134.12 Cr edged up 1.98% from Rs 131.52 Cr, a rise far below the pace of revenue.
- Operating Profit of Rs 250.91 Cr rose 8.35% from Rs 231.57 Cr, sitting between the revenue and net profit growth rates.
- Net profit margin of 9.4% compares with 10.8% in the same quarter last year, a shift the risks section sets out.
- Consolidated basis applies to Strides Pharma Science Q2 Results FY27, and the performance analysis below explains how the three lines moved.
Strides Pharma Science Q2 Results FY27: Performance Analysis
Strides Pharma Science reported consolidated revenue of Rs 1,429.73 Cr, net profit of Rs 134.12 Cr and Operating Profit of Rs 250.91 Cr for July to September 2026. Every line was higher than a year earlier, and revenue grew fastest of the three, as the YoY growth figures show.
Revenue growth of 17.11% took sales from Rs 1,220.83 Cr to Rs 1,429.73 Cr. Strides Pharma Science Q2 Results FY27 show Operating Profit moving from Rs 231.57 Cr to Rs 250.91 Cr, a rise of 8.35%, which means that line grew at about half the pace of sales.
Net profit increased 1.98% from Rs 131.52 Cr to Rs 134.12 Cr, an absolute gain of Rs 2.6 Cr. Across these quarterly results the Strides Pharma Science Q2 Results pattern is consistent, with each profit line trailing the top line, and the results analysis now turns to the business factors behind the numbers.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points first to revenue, which grew 17.1% year on year to Rs 1,429.73 Cr in the latest quarter. This is the sales base against which the profit lines for the quarter are measured.
Net Profit Growth – Net profit rose 2.0% year on year to Rs 134.12 Cr. Strides Pharma Science Q2 Results FY27 therefore record profit growing, though slowly, over the same twelve months, as the supplied record shows.
Returns on Equity and Capital Employed – Return on equity was 20.31% in FY26 and return on capital employed was 18.57% in FY26. These full-year returns sit beside the latest quarterly results and lead into the FY27 outlook.
FY27 Outlook After Strides Pharma Science Q2 Results
The FY27 outlook will depend on the quarters that follow and on disclosed sector conditions, since full-year results are built quarter by quarter. Strides Pharma Science Q2 Results FY27 set a reference point of Rs 134.12 Cr in net profit against which later results can be read from the results date onward.
A useful results analysis of the next filings would track whether YoY growth of 17.11% in revenue continues and whether net profit starts to keep pace with sales. Readers can follow each new disclosure through the Univest app and Univest Screener, and the next section turns to the risks.
Key Risks to Watch After Strides Pharma Science Q2 Results FY27
Net Profit Margin Narrowed
Net profit margin narrowed to 9.4% from 10.8% in the comparison quarter. Strides Pharma Science Q2 Results FY27 show YoY growth of 17.11% in sales, but a smaller share of each rupee of revenue reached net profit.
Debt Is High
Debt is high at 0.54 times total assets in FY26. That balance sheet figure is a full-year reading, and readers can track it in later filings alongside the quarterly profit lines.
Net Profit Down Sequentially
Net profit was down 19.0% quarter on quarter from Rs 165.49 Cr. The latest quarter therefore sits well below the preceding one, a sequential move the conclusion also notes.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Strides Pharma Science Q2 Results FY27 show consolidated revenue of Rs 1,429.73 Cr, up 17.11%, with Operating Profit at Rs 250.91 Cr and net profit at Rs 134.12 Cr, each higher than a year earlier. The narrower margin, the high debt level and the sequential dip remain the points to follow in these consolidated results. Readers comparing the Strides Pharma Science Q2 Results with later quarterly results should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Strides Pharma Science Q2 Results FY27
What are Strides Pharma Science Q2 Results FY27?
Ans. Strides Pharma Science Q2 Results FY27 cover the July to September 2026 quarter, with consolidated revenue of Rs 1,429.73 Cr and net profit of Rs 134.12 Cr, while the Quick Answer box sums up both lines for readers.
What is the results date for Strides Pharma Science Q2 Results FY27?
Ans. The results date was 29 October 2026, when Strides Pharma Science declared its consolidated results for July to September, so the opening paragraphs of this article carry the announcement details.
What revenue was reported in Strides Pharma Science Q2 Results FY27?
Ans. Strides Pharma Science reported consolidated revenue of Rs 1,429.73 Cr, compared with Rs 1,220.83 Cr a year earlier, which means the Financial Highlights table shows a 17.11% YoY rise in sales in these quarterly results.
What net profit was reported in Strides Pharma Science Q2 Results FY27?
Ans. Net profit was Rs 134.12 Cr against Rs 131.52 Cr in the same quarter last year, so the Performance Analysis section records an increase of 1.98% over the year.
How much YoY growth did revenue show in Strides Pharma Science Q2 Results FY27?
Ans. Revenue showed YoY growth of 17.11%, rising from Rs 1,220.83 Cr to Rs 1,429.73 Cr, while the Key Takeaways section places it above the growth recorded by both profit lines.
Did net profit rise or fall in Strides Pharma Science Q2 Results?
Ans. Net profit rose 1.98% to Rs 134.12 Cr in the Strides Pharma Science Q2 Results quarterly results, a pace far below the revenue rise of 17.11%, as the Key Risks section shows.
What was the Operating Profit in Strides Pharma Science Q2 Results FY27?
Ans. In the consolidated results, Operating Profit was Rs 250.91 Cr, up 8.35% from Rs 231.57 Cr, which means it grew slower than revenue, as the Performance Analysis section explains.
Are Strides Pharma Science Q2 Results consolidated results or standalone results?
Ans. These are consolidated results, so the revenue of Rs 1,429.73 Cr and net profit of Rs 134.12 Cr reflect the consolidated basis, as the Quick Answer and the Conclusion both state.
What business factors shaped Strides Pharma Science Q2 Results FY27?
Ans. Revenue growth of 17.1%, net profit growth of 2.0% and a return on equity of 20.31% are among the factors listed, which the Key Business Factors section explains in the results analysis.
What are the key risks after Strides Pharma Science Q2 Results FY27?
Ans. The three risks are a net profit margin of 9.4% against 10.8%, debt at 0.54 times total assets in FY26 and net profit down 19.0% sequentially, as the Key Risks section details.
What is the outlook after Strides Pharma Science Q2 Results?
Ans. FY27 full-year results will depend on the coming quarters and disclosed sector conditions, so net profit of Rs 134.12 Cr serves as a reference point, as the Outlook section explains.
Where can I find the complete Strides Pharma Science Q2 Results FY27 data?
Ans. The complete figures sit in the Financial Highlights table of this article, while the Univest Screener and Univest app give readers a place to follow later filings after the results date, as the Outlook section notes.
